Westlake Village BioPartners is one of seven investors to back ArsenalBio, a San Francisco-based immune cell therapy startup.

ArsenalBio attracted $85 million in Series A financing, according to a statement from Westlake Village Bio on Thursday.

“The technology ArsenalBio is developing represents a significant advance in how cancer could be treated,” said Dr. Beth Seidenberg, co-founder of Westlake Village Bio and general partner at Menlo Park venture capital firm Kleiner Perkins.

“The experience leaders such as Jane Grogan, Michael Kalos and Tarjei Mikkelsen bring, combined with Dr. Drazan’s results-oriented management approach, will help rapidly advance this transformational platform to benefit patients,” she added.

Other investors include the Parker Institute for Cancer Immunotherapy, Kleiner Perkins, the University of California – San Francisco Foundation Investment Co., Euclidean Capital and Osage Venture Partners.

Westlake Village BioPartners is a life sciences-focused venture capital firm in Westlake Village.